NEKTAR THERAPEUTICS (NKTR)       2.72  +0.11 (+4.21%)

2.72  +0.11 (+4.21%)

US6402681083 - Common Stock - After market: 2.72 0 (0%)

NEKTAR THERAPEUTICS2.72

NASDAQ:NKTR (1/31/2023, 7:00:01 PM)+0.11 (+4.21%)

After market: 2.72 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-27 2023-02-27
Ins Owners 1.77% Inst Owners 93.69%
Market Cap 511.23M Shares 187.95M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 49.33
IPO 05-03 1994-05-03

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NKTR Daily chart

Company Profile

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

Company Info

NEKTAR THERAPEUTICS

455 Mission Bay Blvd S

San Francisco CALIFORNIA 94158

P: 14154825300.0

CEO: Howard W. Robin

Employees: 740

Website: https://www.nektar.com/

NKTR News

News Image8 days ago - Market News VideoNotable Tuesday Option Activity: UPWK, NKTR, PFENews Imagea month ago - Nektar TherapeuticsNektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA

/PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual...

News Image2 months ago - Moore Kuehn, PLLCMoore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics...

News Image2 months ago - Nektar TherapeuticsNektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual...

News Image3 months ago - Nektar TherapeuticsNektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for...

News Image3 months ago - BusinessInsiderNektar Therapeutics Reports Third Quarter 2022 Financial Results

SAN FRANCISCO, Nov. 3, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended Septem...

NKTR Twits

Here you can normally see the latest stock twits on NKTR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example